NEW YORK – Clarified Precision Medicine on Friday said that it has completed its acquisition of molecular diagnostics firm Interpares Biomedicine.
The acquisition brings Interpares' genetic sequencing test, OncoGuardian, into Clarified's pipeline of precision medicine diagnostics. Based on patients' DNA sequencing results, OncoGuardian — which Interpares initially licensed from the Moffitt Cancer Center — is designed to determine patients' likelihood of experiencing extreme toxicities during checkpoint inhibitor immunotherapy.
Tampa-based Clarified will now offer OncoGuardian as a complement to its existing product, ClarifiedSelect, which is designed to give doctors and patients clear interpretations of any commercial comprehensive genomic profiling platform. Along with these medical interpretations, Clarified's team of precision oncology experts offer a ranked list of treatment options for each patient.
"When many people refer to precision medicine, they are talking about targeting therapy based on specific variations in tumor DNA," Howard McLeod, Interpares' president, said in a statement. "However, variations in a patient’s DNA may affect the safety and efficacy of specific treatments, including risk of severe or life-threatening adverse events. … Optimally, you want to take into account efficacy as well as safety when deciding what is best for your patient."